The Use of Fractional Ablative CO2 Laser vs Control on Acute Traumatic Injuries to Prevent Scar Formation

Inclusion Criteria: * Subject is between 18 and 80 years of age with burn injuries suffered within the prior 3 months * Subject is a healthy Male or Female * Fitzpatrick Skin Type I - IV * Subject must have moderate - severe burn damage of sufficient bilateral area involving either the face, trunk, arms or legs * Subject must be able to read, understand and sign the Informed Consent Form * Subject must be willing and able to adhere to the treatment and follow-up schedule and post-treatment care instructions * Subject must be willing to have limited sun exposure for the duration of the study, including the follow-up period * Subject is willing to have photographs taken of the treated area which will be used de-identified in evaluations and may be used de-identified in presentations and/or publications * For female candidates - they may be post-menopausal, surgically sterilized, or using a medically acceptable form of birth control during the entire course of the study. * Female candidates with child bearing potential - willing to take pregnancy test and result must be negative. Exclusion Criteria: * Subject is less than 18 or greater than 80 years of age. * Subject has Fitzpatrick Skin Type V - VI * Subject is Pregnant or planning to become pregnant during the study duration * Subject is breast feeding during the study duration * Subject has an active skin infection, dermatitis or a rash in the treatment area * Subject has a history of immunosuppression/immune deficiency disorders or currently using immunosuppressive medications * Subject has a known bleeding disorder * Subject has a known photosensitivity to the study laser wavelength, history of ingesting medications known to induce photosensitivity, or history of seizure disorders due to light. * Subject has a known collagen, vascular disease or scleroderma * Subject has undergone any surgery or other procedures in the treatment area within 6 months of treatment which are still healing. * Subject is suffering from significant concurrent illness, such as insulin-dependent diabetes, peripheral vascular disease or peripheral neuropathy * Subject is undergoing systemic chemotherapy for the treatment of cancer * Subject has lesions suspicious for malignancy * The systemic use of isotretinoin (Accutane®) or other retinoid derivatives within 6 months of study participation * Any use of gold therapy for disorders such as rheumatologic disease or lupus * The subject is excessively tanned in areas to be treated or unable/unlikely to refrain from tanning during the study * The subject has participated in a study of another device or drug within three months prior to enrollment or during the study. * As per the Investigator's discretion, any physical or mental condition which might make it unsafe for the subject to participate in this study